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Available online 19 July 2017Metabolic syndrome (MetSyn) represents a clustering of differentmetabolic abnormalities.MetSyn prevalence is
present in approximately 25% of all adults with increased prevalence in advanced ages. The presence of one com-
ponent ofMetSyn increases the risk of developingMetSyn later in life and likely represents a high lifetimeburden
of cardiovascular disease risk. Therefore we pooled data from multiple studies to establish the prevalence of
MetSyn and MetSyn component prevalence across a broad range of ethnicities. PubMed, SCOPUS and Medline
databases were searched to find papers presenting MetSyn and MetSyn component data for 18–30 year olds
who were apparently healthy, free of disease, and MetSyn was assessed using either the harmonized, National
Cholesterol Education Program Adult Treatment Panel III (NCEP-ATPIII), American Heart Association/National
Heart, Blood and Lung Institute (AHA/NHBLI), or International Diabetes Federation (IDF) definitions of MetSyn.
After reviewing returned articles, 26,609 participants' data from 34 studies were included in the analysis and
the data were pooled. MetSyn was present in 4.8–7% of young adults. Atherogenic dyslipidaemia defined as
lowhigh density lipoprotein (HDL) cholesterol was themost prevalentMetSyn component (26.9–41.2%), follow-
ed by elevated blood pressure (16.6–26.6%), abdominal obesity (6.8–23.6%), atherogenic dyslipidaemia defined
as raised triglycerides (8.6–15.6%), and raised fasting glucose (2.8–15.4%). Thesefindings highlight thatMetSyn is
prevalent in young adults. Establishing the reasonwhy lowHDL is themost prevalent componentmay represent




. This is an open a©2017 TheAuthors. Published by Elsevier Inc. This is an open access article under the CCBY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
MetSyn is an asymptomatic, pathophysiological state characterised
by obesity, insulin resistance, hypertension, dysglycaemia, and
dyslipidaemia (Alberti et al., 2009). While several criteria and defini-
tions have been used to identify MetSyn (Alberti et al., 2009; Grundy
et al., 2005; Alberti et al., 2005; Anon, 2001); it is generally agreed
that a combination of three or more of the following components
must be present: large waist circumference, elevated triglycerides, low
HDL-cholesterol, raised blood pressure, and elevated fasting blood
glucose.
The International Diabetes Federation (IDF) estimates that≈25% of
the world's population has MetSyn (O'Neill and O'Driscoll, 2015) al-
though this estimate varies widely due to the age, ethnicity, and genderin the public,
and.ac.nz
land.ac.nz
ccess article underof the population studied (Kaur, 2014). Having a slightly raised value of
a MetSyn component at a younger age increases the future risk for
MetSyn later in life (Gündogan et al., 2009). Therefore it is important
to establish the prevalence of MetSyn components in young adults
(18–30 years), as the presence of a MetSyn component could represent
a lifetime of increased cardiovascular disease risk. Moreover, the early
identification of MetSyn components could lead to targeted interven-
tions to prevent the development of the syndrome, and thus reduce car-
diovascular disease risk in later life.
Therefore, we performed a pooled analysis of previous literature that
examined the prevalence of MetSyn and components of MetSyn in
young adults with the purpose of determining: 1) the global prevalence
of MetSyn in young adults, and 2) the most prevalent MetSyn compo-
nent in this population.
2. Methods
PubMed, SCOPUS andMedline were searched using the terms “Met-
abolic Syndrome”, “Prevalence”, and “Young Adults” combinedwith the
Boolean operator “AND”. The search was repeated using the term “Col-
lege Students” instead of “Young Adults” and the results combined.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
212 P.B. Nolan et al. / Preventive Medicine Reports 7 (2017) 211–215Duplicates from the returned reference lists were discarded and the list
was consolidated into one list from the three databases.
Abstracts from the returned references were downloaded and were
kept if the abstract indicated that the articlemay contain data relating to
MetSyn and apparently healthy young adults. The remaining articles
were downloaded in full and analysed for specific data relating to
MetSyn in young adults. Studies were included if 1) Participants were
sampled on the basis of being apparently healthy, free of chronic condi-
tions, or having specific anthropometric characteristics; 2) Data were
available in the age range of 18–30 years old; 3) The prevalence for
MetSyn was supplied or able to be calculated; 4) The NCEP-ATP III
criteria (Anon, 2001), Revised NCEP-ATPIII (referred to here as AHA/
NHBLI) criteria (Grundy et al., 2005), International IDF criteria (Alberti
et al., 2005) or the harmonized criteria (Alberti et al., 2009) for MetSyn
were used (Table 1). In addition, the article had to be written in English
and accessible either through open access or our institution's library
subscription that has access to 1200+ databases and 98,000 e-journals.
All papers were cross checked to ensure that data were not used across
multiple studies.
Data relating to MetSyn and MetSyn components in 18–30 year old
adults were extracted from the reviewed articles and MetSyn and
MetSyn component prevalence was calculated using the four different
definitions. The results were tabulated (Table 2).
3. Results
From the initial search, 1276 unique citations were returned, of
which 992 studies were immediately discarded based on the title or ab-
stract. The remaining 284 studies were evaluated against the inclusion
criteria. Thirty-four papers were included in the final review with 11
studies (Bener et al., 2010; da Silveira et al., 2010; Gavrila et al., 2011;
Gündogan et al., 2009; Hildrum et al., 2007; Huang et al., 2007; Li et
al., 2010; Martins et al., 2015; Mikkola et al., 2007; Sy et al., 2014;
Tope et al., 2013) providing MetSyn data based on multiple definitions.
Data from 26,609 different people aged between 18 and 30 years from
17 countries were available for analysis – see table for individual and
grouped prevalence data. Please note that the combined number of ob-
servations for all MetSyn definitions is N26,609 due to the inclusion of
studies using multiple definitions.
Overall MetSyn prevalence was 4.8% (NCEP-ATPIII, n = 333/6889)
5.2% (AHA/NHBLI, n = 643/12473), 7.0% (IDF, n = 971/13953) and
6.5% (harmonized, n = 430/6578). Atherogenic dyslipidaemia
defined as low HDL was the most prevalent MetSyn component
regardless of the criteria used (26.9–41.2%) followed by raised bloodTable 1
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HDL b1.03 mmol/L (male)
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OR taking medication for reduced HDL
b1.03 mmol/L (male)
b1.29 mmol/L (female)
OR taking medication for reduced H
TG ≥1.7 mmol/L or medication for
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≥1.7 mmol/L or medication for
elevated TG
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Diastolic BP or on BP-lowering
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≥130mmHg Systolic BP or ≥85 mm
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FBG ≥5.6 mmol/L or antidiabetic
medication
≥5.6 mmol/L or antidiabetic
medication
MetSyn –metabolic syndrome; WC – abdominal obesity; HDL - atherogenic dyslipidaemia (lo
FBG – raised fasting glucose.pressure (16.6–26.6%), abdominal obesity (6.8–23.6%), atherogenic
dyslipidaemia defined as raised triglycerides (8.6–15.6%), and raised
fasting glucose (2.8–15.4%) (Fig. 1).
4. Discussion
This study provides new information about MetSyn in young adults
in two important ways. First, pooled analysis of a large sample suggests
that 5–7% of young adults have MetSyn. While the prevalence is less
than the IDF estimated prevalence in all adults of 25% worldwide
(O'Neill and O'Driscoll, 2015), the development of MetSyn early in
adulthood can lead to an elevated lifetime burden of cardiovascular dis-
ease risk. Second, one third of all participants had at least one compo-
nent of MetSyn with low HDL being the most prevalent component.
This latterfinding raises the possibility that lowHDLmaybe a keymark-
er identifying early pathology associated with the development of
MetSyn.
Prevention of the development of the first MetSyn component
may have significant public health benefits as the presence of one
component is predictive of the development of MetSyn (Cheung et
al., 2008). Low HDL cholesterol occurs primarily due to increased tri-
glyceride formation reducing cholesterol content of the lipoprotein
core (Eckel et al., 2004). Accordingly, it was expected that a higher
prevalence of raised triglyceride levels would be observed in the cur-
rent findings; however, this did not occur. We speculate that this
could reflect currently unknown mechanisms regarding HDL metab-
olism or a triglyceride cut-off point not calibrated to changes in HDL
levels in young adults. Regardless, while low HDL is not universally
exhibited in all young adults with at least one MetSyn component,
our findings demonstrate that low HDL is the most frequently exhib-
ited MetSyn component regardless of MetSyn definition and may in-
dicate the initiation of pathphysiological processes that underpin the
development of MetSyn for many young adults. Further research
should be undertaken to identify why low-HDL is the most common
component of MetSyn in young adults.
MetSyn component prevalencewas lower than reported for Europe-
an adults from a more diverse and older aged population than the cur-
rent study (Vishram et al., 2014). Approximately 45% of 19–39 year
old adults had the BP component, 25% theWC component, 25% TG com-
ponent, and 20%with HDL component ofMetSyn (Vishram et al., 2014).
Vishramet al. also report an increased prevalence of BP andWC inmales
with increased age with a peak prevalence of elevated TGs and reduced
HDL in the 40–49 year age bracket with a subsequent decline in older
age ranges (50–59, 60–78 years). A similar pattern was observed in2005), NCEP-ATPII (Anon, 2001) and AHA/NHBLI criteria (Grundy et al., 2005).
NCEP-ATPIII AHA/NHBLI








OR taking medication for reduced HDL
b1.03 mmol/L (male)
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Table 2
Prevalence of metabolic syndrome and metabolic syndrome components in 26,609 young adults.
Author Country Total (n) MetSyn WC HDL TG BP FBG
Harmonized Al Dhaheri et al. (2016) UAE 555 38 (6.8) 101 (18.2) 271 (48.8) 8 (1.4) 30 (5.4) 54 (9.7)
Bennett et al. (2014) Jamaica 746 6 (0.8) 108 (14.5) 343 (46.0) 4 (0.5) 154 (20.6) 8 (1.1)
Ferguson et al. (2010) Jamaica 839 10 (1.2) 134 (16.0) 393 (46.8) 5 (0.6) 56 (6.7) 10 (1.2)
Gavrila et al. (2011)a Spain 292 18 (6.2) 81 (27.7) 49 (16.8) 24 (8.2) 48 (16.4) 11 (3.8)
Gupta et al. (2009) India 486 12(2.5) 51 (10.5) 150 (30.9) 27 (5.6) 15 (3.1) 31 (6.4)
Huang et al. (2015) Taiwan 355 24 (6.8) 63 (17.7) 46 (20.6) 32 (9.0) 123 (34.6) 4 (1.1)
Kaduka et al. (2012) Kenya 90 9 (10.0) 17 (18.9) 47 (52.2) 3 (3.3) 51 (56.7) 1 (1.1)
Lin et al. (2014) China 323 22 (6.8) 180 (55.7) 63 (19.5) 40 (12.4) 20 (6.2) 22 (6.8)
Martins et al. (2015)a Brazil 2031 242 (9.0) 646 (31.8) 851 (41.9) 254 (12.5) 465 (22.9) 73 (3.6)
Sy et al. (2014)a Philippines 861 108 (12.5) 173 (20.1) 467 (54.2) 171 (19.9) 127 (14.8) 144 (16.7)
Overall 6578 430 (6.5%) 1554 (23.6%) 2707 (41.2%) 568 (8.6%) 1089 (16.6%) 358 (5.4%)
NCEP –ATPIII Erem et al. (2008) Turkey 1306 93 (7.1) 182 (13.9) 318 (21.3) 183 (14.0) 424 (32.5) 25 (1.9)
Gündogan et al. (2009)a Turkey 84 10 (11.9) 25 (29.8) 19 (22.6) 24 (28.6) 20 (23.8) 11 (13.1)
Huang et al. (2004) USA 163 1 (0.6) 3 (1.8) 22 (13.5) 4 (2.5) 2 (1.2) 3 (1.8)
Li et al. (2010)a China 2532 101 (4.0) 79 (3.1) 742 (29.3) 241 (9.5) 519 (20.5) 58 (2.3)
Manjunath et al. (2014) India 473 41 (8.7) 76 (16.1) 184 (38.9) 37 (7.8) 123 (26.0) 42 (8.9)
Mikkola et al. (2007)a Finland 1099 38 (3.5) 51 (4.6) 212 (19.3) 31 (2.8) 565 (51.4) 25 (2.3)
Sidorenkov et al. (2010) Russia 862 23 (2.7) 19 (2.2) 266 (30.9) 83 (9.6) 149 (17.3) 6 (0.7)
Sinha et al. (2013) India 85 8 (9.4) 18 (21.2) 53 (62.4) 18 (21.2) 5 (5.9) 7 (8.2)
Soysal et al. (2005) Turkey 285 18 (6.3) 14 (4.9) 40 (14.0) 115 (40.4) 25 (8.8) 13 (4.6)
Overall 6889 333 (4.8%) 467 (6.8%) 1856 (26.9%) 736 (10.7%) 1832 (26.6%) 190 (2.8%)
IDF Bener et al. (2009)a Qatar 203 16 (7.9) 16 (7.9) 43 (21.2) 30 (14.8) 34 (16.7) 8 (3.9)
da Costa et al. (2011) Brazil 711 28 (3.9) 90 (12.7) 313 (44.0) 35 (4.9) 71 (10.0) 35 (1.4)
da Silveira et al. (2010)a Brazil 3599 240 (6.7) 618 (17.2) 694 (19.3) 598 (16.6) 883 (24.5) 1322 (36.7)
Gavrila et al. (2011)a Spain 292 18 (6.2) 81 (27.7) 49 (16.8) 24 (8.2) 48 (16.4) 11 (3.8)
Gündogan et al. (2009)a Turkey 84 16 (19.0) 25 (29.8) 19 (22.6) 24 (28.6) 20 (23.8) 11 (13.1)
Hildrum et al. (2007)a Norway 1615 19 (1.2) 414 (25.6) 459 (28.4) 221 (13.7) 499 (30.9) 179 (11.1)
Huang et al. (2007)a USA 300 2 (0.7) 8 (2.7) 73 (24.3) 27 (9.0) 11 (3.7) 27 (9.0)
Kanitkar et al. (2015) India 250 55 (22.0) 139 (55.6) 93 (37.2) 71 (29.2) 21 (8.4) 44 (17.6)
Li et al. (2010)a China 2532 147 (5.8) 79 (3.1) 742 (29.3) 241 (9.5) 519 (20.5) 58 (2.3)
Martins et al. (2015)a Brazil 2031 242 (11.9) 646 (31.8) 851 (41.9) 254 (12.5) 465 (22.9) 73 (3.6)
Mikkola et al. (2007)a Finland 1099 75 (6.8) 134 (12.2) 212 (19.3) 31 (2.8) 565 (51.4) 221 (20.1)
Sy et al. (2014)a Philippines 861 108 (9.1) 173 (20.1) 467 (54.2) 171 (19.9) 127 (14.8) 144 (16.7)
Tope et al. (2013)a USA 376 35 (9.3) 43 (11.4) 73 (19.4) 21 (5.6) 38 (10.1) 42(11.2)
Overall 13,953 971 (7.0%) 2466 (17.7%) 4088 (29.3%) 1750 (12.5%) 3301 (23.7%) 2150 (15.4%)
AHA/NHBLI Bener et al. (2009)a Qatar 203 15 (7.4) 16 (7.9) 43 (21.2) 30 (14.8) 34 (16.7) 8 (3.9)
Cheserek et al. (2014) China 200 1 (0.5) 4 (2.0) 19 (9.5) 13 (6.5) 24 (12.0) 6 (3.0)
da Silveira et al. (2010)a Brazil 3599 213 (5.9) 269 (7.5) 694 (19.3) 598 (16.6) 883 (24.5) 610 (16.9)
Dalleck and Kjelland (2012) USA 207 14 (6.8) 12 (5.8) 98 (47.3) 28 (13.5) 34 (16.4) 15 (7.2)
de Kroon et al. (2008) Netherlands 642 48 (7.5) 78 (12.1) 187 (29.1) 50 (7.8) 274 (42.7) 75 (11.7)
Fernandes and Lofgren (2011) USA 189 7 (3.7) 14 (7.4) 38 (20.1) 33 (17.5) 4 (2.1) 14 (7.4)
Gavrila et al. (2011)a Spain 292 10 (3.4) 31 (10.6) 49 (16.8) 24 (8.2) 48 (16.4) 11 (3.8)
Hildrum et al. (2007)a Norway 1615 19 (1.2) 414 (25.6) 459 (28.4) 221 (13.7) 499 (30.9) 179 (11.1)
Huang et al. (2007)a USA 300 4 (1.3) 8 (2.7) 73 (24.3) 27 (9.0) 11 (3.7) 27 (9.0)
Morrell et al. (2013) USA 1610 81 (5.0) 209 (130) 467 (29.0) 258 (16.0) 403 (25.0) 64 (4.0)
Morrell et al. (2012) USA 2103 103 (4.9) 94 (4.5) 538 (25.6) 350 (16.6) 681 (32.4) 177 (8.4)
Shahbazian et al. (2013) Iran 203 13 (6.4) 26 (12.8) 85 (41.9) 47 (23.2) 1 (0.5) 35 (17.2)
Sharifi et al. (2009) Iran 934 70 (7.5) 31 (9.7) 714 (76.4) 246 (26.3) 56 (6.0) 74 (7.9)
Tope et al. (2013)a USA 376 45 (12.0) 43 (11.4) 73 (19.4) 21 (5.6) 38 (10.1) 42 (11.2)
Overall 12,473 643 (5.2%) 1309 (10.5%) 3537 (28.4%) 1946 (15.6%) 2990 (24.0%) 1337 (10.7%)
Data are expressed as n (%).
MetSyn –metabolic syndrome; WC – abdominal obesity; HDL - atherogenic dyslipidaemia (low HDL); TG - atherogenic dyslipidaemia (raised triglycerides); BP - raised blood pressure;
FBG – raised fasting glucose.
a Indicates study used more than one definition of MetSyn and is included multiple times.
213P.B. Nolan et al. / Preventive Medicine Reports 7 (2017) 211–215females except TG prevalence increased with age and only HDL preva-
lence is decreased in ages above 40–49 years. Therefore, prevalence of
MetSyn components in young adults is expected to increase up to the
age of 50.
While overall MetSyn prevalence was similar between the four
MetSyn definitions, a wide range of prevalence was present for each
MetSyn component. Differences in WC prevalence can be partially ex-
plained by the use of ethnic specific thresholds in the harmonized and
IDF definitions but the difference in HDL, BP, and FBG prevalence, can-
not be explained by the definition. Therefore, it is possible that these ob-
servations indicate young adults from different ethnicities are more
prone to develop different components ofMetSyn. Therefore, a possibil-
ity worth exploring is that all MetSyn component thresholds may be
ethnic specific and thus specific ethnic thresholds for each MetSyncomponent may need to be developed to accurately assess MetSyn.
This is similar to current recommendations of using ethnic specific
thresholds for WC.5. Conclusion
MetSyn prevalence ranges from 5 to 7% in young adults. Low HDL is
themost prevalent component of MetSyn in young adults and thusmay
also be the first detectable component of MetSyn inmany young adults.
Exploring the importance and significance of low HDL in young adults
may have considerable public health benefit as interventions aimed at
improving low HDL cholesterol levels could reduce future incidence of
MetSyn and subsequent clinical disease.
Fig. 1. Prevalence of metabolic syndrome and metabolic syndrome components in 26,609 young adults according to fourmetabolic syndrome criteria. MetSyn –metabolic syndrome;
WC – abdominal obesity; HDL - atherogenic dyslipidaemia (low HDL); TG - atherogenic dyslipidaemia (raised triglycerides); BP - raised blood pressure; FBG – raised fasting glucose.
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